ENVESTNET ASSET MANAGEMENT INC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 335 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.07 and the average weighting 0.2%.

Quarter-by-quarter ownership
ENVESTNET ASSET MANAGEMENT INC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$8,228,471
+60.5%
215,405
+51.5%
0.00%
+100.0%
Q2 2023$5,127,170
-13.3%
142,145
-51.3%
0.00%
-33.3%
Q1 2023$5,915,367
-26.7%
292,016
+105.9%
0.00%
-25.0%
Q4 2022$8,068,306
+59.4%
141,798
+10.7%
0.00%
+33.3%
Q3 2022$5,063,000
+63.9%
128,044
+82.3%
0.00%
+50.0%
Q2 2022$3,090,000
+19.8%
70,230
+8.6%
0.00%
+100.0%
Q1 2022$2,579,000
+5.5%
64,678
+6.4%
0.00%0.0%
Q4 2021$2,445,000
-1.3%
60,799
-0.1%
0.00%0.0%
Q3 2021$2,477,000
+17.0%
60,890
+30.6%
0.00%0.0%
Q2 2021$2,117,000
+16.9%
46,620
+7.3%
0.00%0.0%
Q1 2021$1,811,000
+53.2%
43,442
+57.0%
0.00%0.0%
Q4 2020$1,182,000
+58.7%
27,673
-2.4%
0.00%0.0%
Q3 2020$745,000
+79.1%
28,351
+82.5%
0.00%
Q2 2020$416,000
+47.0%
15,532
-1.1%
0.00%
Q1 2020$283,000
+6.4%
15,706
+4.6%
0.00%
Q4 2019$266,000
+19.3%
15,010
+4.4%
0.00%
Q3 2019$223,000
-7.5%
14,383
+2.5%
0.00%
Q2 2019$241,000
+8.6%
14,039
+2.0%
0.00%
Q1 2019$222,000
-15.9%
13,759
-23.8%
0.00%
Q4 2018$264,00018,053
+138769.2%
0.00%
Q4 2016$0
-100.0%
13
-99.2%
0.00%
Q1 2016$16,000
-36.0%
1,643
+16.2%
0.00%
Q4 2015$25,000
+78.6%
1,414
+39.2%
0.00%
Q3 2015$14,0001,0160.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2021
NameSharesValueWeighting ↓
SNYDER CAPITAL MANAGEMENT L P 4,324,232$165,185,6623.73%
Steamboat Capital Partners, LLC 196,898$7,521,5042.79%
2Xideas AG 600,799$22,950,5222.54%
BERNZOTT CAPITAL ADVISORS 171,808$6,563,0662.26%
Redwood Investments, LLC 328,459$12,547,1341.70%
Mesirow Institutional Investment Management, Inc. 380,415$14,531,8531.47%
Granite Investment Partners, LLC 856,253$32,708,8651.37%
Penn Capital Management Company, LLC 324,707$12,453,2111.28%
EFG Asset Management (North America) Corp. 137,739$5,262,3191.25%
First Light Asset Management, LLC 313,536$11,977,0751.14%
View complete list of HALOZYME THERAPEUTICS INC shareholders